A Kentucky defective product lawyer would want the public to be aware that pharmaceutical company Pfizer recalled 100,000 bottles of the painkiller Embeda from wholesalers and retailers in the United States, because it was shown not to meet stability standards. This recall is the latest is a series of product recalls for Pfizer, who purchased King Pharmaceuticals at the end of 2010 for over three billion dollars. Previous recalls included Lipitor and Caverject.
Pfizer claims that using Embeda as prescribed would not pose a safety risk and those patients currently using it may continue to do so for their remaining supply. The recall was ordered by the company after routine testing found that the drug level of one of the ingredients was higher than expected; all dosage forms of Embeda extended –release capsules are subject. Embeda is classified as a CII, or C2 controlled substance, meaning it has a high potential for abuse, however, if the drug is used as prescribed, there should be no serious side effects. Nevertheless, patients who use Embeda should consult their doctors about finding alternate pain treatments until the current issue is resolved.